TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10604047
Drug: LR patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: LR patch (50 micrograms/day estradiol)
Study: 10604047
Drug: SAM patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAM patch
Study: 10604047
Drug: LR patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: LR patch
Study: 7729633
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg three times a day) + Amoxicillin (750 mg three times a day)
Study: 7729633
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg three times a day) + Placebo (750 mg three times a day)
Study: 2202163
Drug: 5% cyclosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% cyclosporin in an ointment base under occlusion
Study: 7408414
Drug: Naloxone 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 0.8 mg intravenously
Study: 7408414
Drug: Morphine 15
Normalized name: morphine 15 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 15 mg intravenously
Study: 26787629
Drug: Cholecalciferol 50
Normalized name: cholecalciferol 50 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 50 000 IU weekly for 8 weeks, then 50 000 IU monthly for 2 months (group A)
Study: 26787629
Drug: Cholecalciferol 7000
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 7000 IU daily for 8 weeks, then 12 500 IU weekly for 2 months (group B)
Study: 16925685
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with a cumulative dose of around 41824 IR, equivalent to 1.7 mg of D.p. and 3.0 mg of D.f. allergen for 6 months.
Study: 9593493
Drug: SDR plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDR plus physical therapy (PT)
Study: 2244793
Drug: Imipramine hydrochloride
Normalized name: Imipramine Hydrochloride
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imipramine hydrochloride maintained at an average dose of 200 mg
Study: 2244793
Drug: Monthly interpersonal
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly interpersonal psychotherapy
Study: 28079828
Drug: PHiD-CV primary
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHiD-CV primary vaccination and booster dose
Study: 17915636
Drug: Carbamazepine immediate
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine immediate release tablet formulation 1
Study: 17915636
Drug: Carbamazepine immediate
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine immediate release tablet formulation 2
Study: 15334791
Drug: Glimepiride (3+/−1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (3+/−1 mg/d)
Study: 15334791
Drug: Metformin (2500+/−500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2500+/−500 mg/d)
Study: 19864905
Drug: Toothpaste containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toothpaste containing 1,190 mg/kg fluoride as 0.76% SMFP
Study: 15155420
Drug: AAS administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AAS administration for 8 or 14 weeks
Study: 15155420
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (200 mg/week) for 8 weeks
Study: 11477839
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus concentrated Xuefu Zhuyu Pill (CXZP)
Study: 2665351
Drug: PVRV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVRV vaccine (new inactivated rabies vaccine grown on Vero cells)
Study: 2665351
Drug: HDCV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDCV vaccine (rabies vaccine cultivated on human diploid cells)
Study: 30598
Drug: Flunitrazepam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (0.5 mg)
Study: 6994369
Drug: Meprobamate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meprobamate (200 mg)
Study: 31328807
Drug: Ivabradine hemisulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine hemisulfate sustained-release tablets 5 mg
Study: 31328807
Drug: Ivabradine hemisulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine hemisulfate sustained-release tablets 10 mg
Study: 31328807
Drug: Ivabradine hemisulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine hemisulfate sustained-release tablets 15 mg
Study: 31328807
Drug: N-desmethyl ivabradine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-desmethyl ivabradine 5 mg
Study: 31328807
Drug: N-desmethyl ivabradine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-desmethyl ivabradine 10 mg
Study: 31328807
Drug: N-desmethyl ivabradine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-desmethyl ivabradine 15 mg
Study: 29033294
Drug: Acetaminophen 4,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 4,000 mg/day
Study: 11361192
Drug: Ibuprofen 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 1,200 mg/day
Study: 7803332
Drug: Midazolam (0.15‐0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.15‐0.20 mg/kg)
Study: 7803332
Drug: Thiopentone (4‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (4‐6 mg/kg)
Study: 23918455
Drug: Intranasal pulmonary
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal pulmonary surfactant (PS)
Study: 21403524
Drug: Quetiapine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (50 mg/day)
Study: 18179001
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 70% isopropyl alcohol
Study: 18179001
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg granisetron IV
Study: 18179001
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic treatment control
Study: 11135716
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of saline for 12 h (Group A: 169 patients)
Study: 11135716
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of tranexamic acid, 1 mg x kg(‐1) x h(‐1) for 12 h (Group B: 171 patients)
Study: 11135716
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of tranexamic acid, 2 mg x kg(‐1) x h(‐1) for 12 h (Group C: 170 patients)
Study: 9821028
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dose of two capsules of Cyclo 3 Fort in the morning
Study: 9821028
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily dose of one capsule of Cyclo 3 Fort morning and noon
Study: 7978434
Drug: Placebo PO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo PO + tetracaine 12 mg IT
Study: 7978434
Drug: Placebo PO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo PO + tetracaine 12 mg IT + fentanyl 10 micrograms IT
Study: 7978434
Drug: Clonidine 200
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 200 micrograms PO + tetracaine 12 mg IT
Study: 7978434
Drug: Clonidine 200
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 200 micrograms PO + tetracaine 12 mg IT + fentanyl 10 micrograms IT
Study: 29202277
Drug: Clobazam (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (0.25, 0.50, or 1.0 mg/kg/d) during lead-in; Clobazam up to 2.0 mg/kg/d (maximum 80 mg/d) during OLE
Study: 29202277
Drug: Clobazam dosage
Normalized name: Clobazam
DrugBank: Clobazam (DB00349)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clobazam dosage increase of ≥ 20% during long-term treatment
Study: 26633145
Drug: Endotracheal tube
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endotracheal tube (ETT) with premedication (atropine and morphine)
Study: 17277392
Drug: Anti-platelet agents
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-platelet agents
Study: 20422948
Drug: Itraconazole capsule
Normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole capsule formulation
Study: 18043456
Drug: 3-day therapy
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-day therapy with amoxicillin-clavulanate
Study: 18043456
Drug: 10-day therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-day therapy with amoxicillin-clavulanate
Study: 10385765
Drug: Methylprednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (1 g intravenously infused 6 to 12 hours before stenting)
Study: 8625084
Drug: Helium-neon laser
Normalized name: neon
DrugBank: Neon (DB11589)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helium-neon laser treatment
Study: 2205527
Drug: Ranitidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (400 mg per day for 5 days)
Study: 2205527
Drug: Omeprazole (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (80 mg per day for 5 days, 120 mg on the 1st day)
Study: 22791282
Drug: Non-xylitol treatment
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-xylitol treatment
Study: 21956721
Drug: OnabotulinumtoxinA (155
Approvals — FDA: no, EMA: no, PMDA: no
Description: OnabotulinumtoxinA (155 U, 31 injections of 5U each, with an additional 40 U as needed)
Study: 19695562
Drug: Written treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written treatment manual
Study: 17146104
Drug: Gabapentin plus
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin plus antidepressant
Study: 15179390
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with either a headgear or a functional appliance
Study: 11209119
Drug: Sequential pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential pulse therapy with itraconazole (200 mg twice daily for 1 week) followed by terbinafine (250 mg twice daily for 1 week)
Study: 11209119
Drug: Terbinafine pulse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine pulse therapy (3 or 4 pulses of terbinafine)
Study: 28967523
Drug: Bovine-human reassortant
Normalized name: human-bovine reassortant rotavirus strain G4 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine-human reassortant pentavalent rotavirus vaccine (BRV-PV)
Study: 10600433
Drug: Parents as
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parents as sole agents of change (experimental group)
Study: 10600433
Drug: Children as
Normalized name: AZELASTINE HYDROCHLORIDE 205.5 ug NASAL SPRAY, METERED [Children Astepro Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children as sole agents of change (conventional group)
Study: 2009851
Drug: Four units
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four units of alcohol (approx. 70 mg alcohol/100 ml blood)
Study: 2009851
Drug: Two units
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two units of alcohol (approx. 35 mg alcohol/100 ml blood)
Study: 2009851
Drug: Nil units
Normalized name: Ipomoea nil seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nil units of alcohol (less than 5 mg alcohol/100 ml blood)
Study: 27929673
Drug: Gadoxetate disodium
Normalized name: Gadoxetate Disodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadoxetate disodium (10 mL diluted 1:1 with saline; injection rate, 2 mL/s)
Study: 27929673
Drug: Gadobenate dimeglumine
Normalized name: Gadobenate Dimeglumine
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadobenate dimeglumine (0.2 mL/kg; maximum, 20 mL; injection rate, 2 mL/s)
Study: 22673738
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose macrolides
Study: 21384253
Drug: Homogenised spinach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homogenised spinach (225 g/day/person)
Study: 9122358
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral naltrexone
Study: 2434792
Drug: Cilazapril 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 1.25 mg p.o. q.d.
Study: 2434792
Drug: Cilazapril 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 5.0 mg p.o. q.d.
Study: 29075824
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Bevacizumab and Everolimus (dual-therapy)
Study: 29075824
Drug: Dual-therapy in
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-therapy in normal liver (Arm E)
Study: 29075824
Drug: Dual-therapy in
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-therapy in normal liver (Arm B)
Study: 16882058
Drug: 25 mg/day
Normalized name: estradiol 0.025 MG/Day Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/day naftopidil (Group LD)
Study: 16882058
Drug: 75 mg/day
Normalized name: Lyllana 0.075 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/day naftopidil (Group HD)
Study: 14661012
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1500 mg, starting the evening before angiography and given every 12 hours for 4 doses
Study: 8795667
Drug: Lysine aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine aspirin 900 mg
Study: 8795667
Drug: Sodium salicylate
Normalized name: Sodium Salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium salicylate 800 mg
Study: 8795667
Drug: 9.5% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.5% saline with indomethacin 50 mg
Study: 6600677
Drug: Naproxen 250
Normalized name: naproxen 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 250 mg
Study: 12421160
Drug: Naproxen 375
Normalized name: naproxen 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 375 mg
Study: 30878329
Drug: Standard training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard training plus additional weekly simulation training
Study: 30878329
Drug: Standard training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard training plus additional weekly simulation training (standardized to supervisor's performance)
Study: 28366341
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy including parent involved play (CBT-PIP)
Study: 28366341
Drug: Non-directive treatment
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-directive treatment (TEPT; triadic expressive play therapy)
Study: 27092916
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A injection prior to implant placement
Study: 27092916
Drug: No Botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Botulinum toxin type A injection (Control group)
Study: 24703078
Drug: BROADLINE(®) at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: BROADLINE(®) at 0.12 mg/kg body weight
Study: 22116799
Drug: Macrolide antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macrolide antibiotics (e.g., erythromycin, azithromycin)
Study: 22116799
Drug: No macrolide
Approvals — FDA: no, EMA: no, PMDA: no
Description: No macrolide antibiotics (Control)
Study: 22116799
Drug: Fluoroquinolone antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroquinolone antibiotics (n = 90)
Study: 22116799
Drug: Cephalosporin antibiotics
Normalized name: Cephalosporium roseum
DrugBank: Cephalosporium roseum (DB10932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalosporin antibiotics (n = 93)
Study: 12465006
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (ORIF with IMF and ORIF without IMF)
Study: 10211915
Drug: Trihexyphenidyl (THP)
DrugBank: Trihexyphenidyl (DB00376)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trihexyphenidyl (THP) dose reduction by 1 mg every 2 weeks
Study: 10211915
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no dose reduction)
Study: 2371034
Drug: d-fenfluramine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-fenfluramine (15 mg twice daily)
Study: 24705623
Drug: Cilostazol and
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol and probucol combination therapy
Study: 19032525
Drug: Cinacalcet (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet (administered for 7-14 months)
Study: 1984829
Drug: 7-3 therapy
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-3 therapy (cytarabine 100 mg/m2 on days 1 to 7 plus daunorubicin 50 mg/m2 on days 1 to 3)
Study: 1984829
Drug: 7-3-7 therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-3-7 therapy (cytarabine 100 mg/m2 on days 1 to 7 plus daunorubicin 50 mg/m2 on days 1 to 3 plus etoposide 75 mg/m2 on days 1 to 7)
Study: 1984829
Drug: 7-3 therapy
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-3 therapy
Study: 1984829
Drug: 7-3-7 therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-3-7 therapy
Study: 1984829
Drug: 7-3 therapy
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-3 therapy (subset analysis for patients younger than 55 years)
Study: 1984829
Drug: 7-3-7 therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-3-7 therapy (subset analysis for patients younger than 55 years)
Study: 32044
Drug: Terfenadine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 20 mg
Study: 26437449
Drug: Multi-dimensional and
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-dimensional and inter-sectoral intervention program including therapy simplification and individualized patient education during hospital stay and up to three months after discharge, with subsequent phone calls after discharge.
Study: 21883123
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 μg.kg(‐1)
Study: 21883123
Drug: Morphine 100
Normalized name: MORPHINE 100MG/NALTREXONE 4MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 100 μg.kg(‐1)
Study: 19609165
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor muscle (PFM) training for 8 weeks, including 3 sets of daily fast and slow contractions in various positions and weekly motivational calls.
Study: 17716312
Drug: Sub-antimicrobial dose
Normalized name: DAB(SUB 389)IL2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-antimicrobial dose doxycycline (SDD; 20 mg bid)
Study: 14755150
Drug: Helicobacter pylori
Normalized name: HELICOBACTER PYLORI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helicobacter pylori eradication therapy (specifics not provided)
Study: 14755150
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg daily for 12 months
Study: 9853852
Drug: Intramesosalpingeal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramesosalpingeal injection of 20 IU oxytocin diluted to 20 ml with saline solution
Study: 9853852
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml saline solution (control)
Study: 2687142
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg at night (single dose)
Study: 31443993
Drug: Co-Administration group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-Administration group (RZV dose 1 and Tdap at Day 0, RZV dose 2 at Month 2)
Study: 31443993
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Tdap at Day 0, RZV dose 1 at Month 2, RZV dose 2 at Month 4)
Study: 31443993
Drug: Co-Administration group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-Administration group and Control group
Study: 25026944
Drug: Inner relationship
Normalized name: isosulfan blue inner salt
DrugBank: Isosulfan blue (DB09136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inner relationship focusing (20‐h course followed by 5 months of weekly sessions)
Study: 23625433
Drug: Pitavastatin 4
Normalized name: PITAVASTATIN 4MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 4 mg/d for 5 days
Study: 17091656
Drug: Adper Prompt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adper Prompt L‐Pop (APL)
Study: 11583750
Drug: Radical nephrectomy
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical nephrectomy plus interferon-alfa-based immunotherapy (5x10(6) IU/m(2) subcutaneously three times per week)
Study: 7869303
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg pamidronate
Study: 7869303
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pamidronate
Study: 2450722
Drug: Prophylactic chemotherapy
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic chemotherapy with 5-FU via the recanalized umbilical vein in patients without liver metastases
Study: 2450722
Drug: Intraportal adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraportal adjuvant chemotherapy after resection of liver metastases
Study: 2450722
Drug: Intraarterial chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial chemotherapy in patients with unresectable liver metastases
Study: 30249314
Drug: Cottage cheese
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cottage cheese (CC) - 30 g of protein, 10 g of carbohydrate, 0 g of fat